ATE267255T1 - Ob proteinderivate mit verlängerter halbwertzeit - Google Patents

Ob proteinderivate mit verlängerter halbwertzeit

Info

Publication number
ATE267255T1
ATE267255T1 AT96945295T AT96945295T ATE267255T1 AT E267255 T1 ATE267255 T1 AT E267255T1 AT 96945295 T AT96945295 T AT 96945295T AT 96945295 T AT96945295 T AT 96945295T AT E267255 T1 ATE267255 T1 AT E267255T1
Authority
AT
Austria
Prior art keywords
life
extended half
derivatives
protein derivatives
whether protein
Prior art date
Application number
AT96945295T
Other languages
German (de)
English (en)
Inventor
Sauvage Frederic J De
Nancy Levin
Richard L Vandlen
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE267255T1 publication Critical patent/ATE267255T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT96945295T 1995-12-27 1996-12-19 Ob proteinderivate mit verlängerter halbwertzeit ATE267255T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57949495A 1995-12-27 1995-12-27
US66718496A 1996-06-20 1996-06-20
PCT/US1996/020718 WO1997024440A1 (en) 1995-12-27 1996-12-19 Ob protein derivatives having prolonged half-life

Publications (1)

Publication Number Publication Date
ATE267255T1 true ATE267255T1 (de) 2004-06-15

Family

ID=27077779

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96945295T ATE267255T1 (de) 1995-12-27 1996-12-19 Ob proteinderivate mit verlängerter halbwertzeit

Country Status (14)

Country Link
EP (1) EP0870026B1 (enExample)
JP (1) JP4037905B2 (enExample)
CN (1) CN1154726C (enExample)
AT (1) ATE267255T1 (enExample)
AU (1) AU1520097A (enExample)
BR (1) BR9612359A (enExample)
CA (1) CA2238307A1 (enExample)
CZ (1) CZ9802013A3 (enExample)
DE (1) DE69632546T2 (enExample)
IL (1) IL124831A0 (enExample)
MX (1) MX9804687A (enExample)
NZ (1) NZ326592A (enExample)
RU (1) RU2178307C2 (enExample)
WO (1) WO1997024440A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
EP0741187A2 (en) * 1995-05-05 1996-11-06 F. Hoffmann-La Roche Ag Recombinant obese (Ob) proteins
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
DK0866720T3 (da) * 1995-11-22 2004-06-14 Amgen Inc OB-protein til forögelse af mager kropsmasse
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
CN1195858C (zh) * 1996-12-20 2005-04-06 安姆根有限公司 Ob融合蛋白组合物及方法
AU770897B2 (en) * 1996-12-20 2004-03-04 Amgen, Inc. OB fusion protein compositions and methods
CA2286098C (en) * 1997-04-17 2009-07-07 Amgen Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
AU2002300605B8 (en) * 1997-04-17 2006-02-09 Amgen Inc. Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods
US6017876A (en) * 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
JP4336452B2 (ja) 1997-12-08 2009-09-30 メルク パテント ゲーエムベーハー 標的化免疫治療および一般の免疫刺激に対して有用である二量体融合タンパク質
EP1074564B1 (en) 1998-04-23 2008-12-10 Ajinomoto Co., Inc. Substance with antithrombotic activity and method for detecting glycokallidin
US6492138B1 (en) 1998-05-21 2002-12-10 Amgen Canada Inc. Polynucleotides encoding a novel SHC-binding protein
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
BR0013231A (pt) 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
WO2001036489A2 (en) 1999-11-12 2001-05-25 Merck Patent Gmbh Erythropoietin forms with improved properties
MXPA02007733A (es) 2000-02-11 2004-09-10 Merck Patent Gmbh Mejoramiento de la vida media circulante de proteinas de fusion basadas en anticuerpos.
PL358582A1 (en) 2000-06-29 2004-08-09 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
AU2002252035A1 (en) * 2001-02-21 2002-09-12 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
PL206701B1 (pl) 2001-03-07 2010-09-30 Merck Patent Gmbh Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
KR100900166B1 (ko) 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
EP2354791A1 (en) 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
AU2003298187B2 (en) 2002-12-17 2010-09-16 Merck Patent Gmbh Humanized antibody (H14.18) of the mouse 14.18 antibody binding to GD2 and its fusion with IL-2
JP2006514990A (ja) 2002-12-27 2006-05-18 ディオベックス， インコーポレイテッド インスリン誘発性低血糖の予防および制御のための組成物および方法
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
EP2239273B1 (en) * 2003-11-13 2013-10-09 Hanmi Science Co., Ltd. A pharmaceutical composition comprosing an immunoglobulin fc as a carrier
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
CA2551916C (en) 2003-12-31 2014-04-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Fc-erythropoietin fusion protein with improved pharmacokinetics
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
KR100639397B1 (ko) * 2004-03-18 2006-10-26 (주)에스제이바이오메드 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
BRPI0519000A2 (pt) 2004-12-09 2008-12-23 Merck Patent Gmbh variantes de il-7 com imunogenicidade reduzida
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
AU2009248914A1 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for Treating Neurodegenerative Disorders Related to Neurofibrillary Tangles
EA201171259A1 (ru) 2009-04-22 2012-05-30 Мерк Патент Гмбх Антительные гибридные белки с модифицированными сайтами связывания fcrn
CN104147596A (zh) * 2013-05-14 2014-11-19 李荣秀 生物药非共价结合聚合物延长治疗浓度的方法及用途
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
EP0741187A2 (en) * 1995-05-05 1996-11-06 F. Hoffmann-La Roche Ag Recombinant obese (Ob) proteins
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound

Also Published As

Publication number Publication date
CA2238307A1 (en) 1997-07-10
NZ326592A (en) 2001-05-25
JP4037905B2 (ja) 2008-01-23
BR9612359A (pt) 1999-07-13
IL124831A0 (en) 1999-01-26
CN1205738A (zh) 1999-01-20
MX9804687A (es) 1998-10-31
CN1154726C (zh) 2004-06-23
EP0870026A1 (en) 1998-10-14
EP0870026B1 (en) 2004-05-19
JP2000504210A (ja) 2000-04-11
AU1520097A (en) 1997-07-28
WO1997024440A1 (en) 1997-07-10
DE69632546D1 (de) 2004-06-24
DE69632546T2 (de) 2005-06-30
RU2178307C2 (ru) 2002-01-20
CZ9802013A3 (cs) 1998-09-16

Similar Documents

Publication Publication Date Title
ATE267255T1 (de) Ob proteinderivate mit verlängerter halbwertzeit
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
PL341524A1 (en) Novel receptor coupled wih g protein
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
DE69432109D1 (de) Synthetische, vielfache tandemwiederholungen des mucinpeptides und seiner derivate und deren verwendung
DE69807679D1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
ATE239797T1 (de) Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
DK0754229T3 (da) Afamin: et humant serum albumin-lignende protein
ATE322503T1 (de) Gefrierschutzprotein
DK0601154T3 (da) BPC-peptider, deres fremstilling og anvendelse
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
ATE527358T1 (de) Ribosomen inaktivierendes protein vom typ-1
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
BG101038A (bg) Супресия на растежа на туморни клетки посредствомсиндекан- 1 ектоучастък
SE9602822D0 (sv) New receptor
CA2090701A1 (en) Solubilization of proteins in active forms
ATE309270T1 (de) ßSMOOTHENEDß PROTEINE AUS WIRBELTIEREN
WO1998016255A3 (en) Stabilized conjugates of uncomplexed subunits of multimeric proteins
ATE432292T1 (de) Antitumorantikörper, proteine und deren verwendung
NO992531L (no) Fremgangsmåter ved fremstilling av rekombinant protein
DE59509948D1 (de) Konjugat aus einem wirkstoff und einem nicht als körperfremd angesehenen, nativen protein
ATE362531T1 (de) Interne ribosom eintrittstelle (ires), vektor der diesen enthaltet und dessen therapeutische verwendung
SE9604439D0 (sv) New receptor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0870026

Country of ref document: EP